Jeremy Shefner, MD, PhD, is Professor and Chief Medical Officer for Clinical Research at the Barrow Neurological Institute. He earned his medical degree from Northwestern University Medical School and his doctorate in sensory physiology from the University of Illinois. He completed his residency at Harvard Longwood Neurology Training Program and his fellowship in clinical neurophysiology at Brigham and Women’s Hospital.
Dr. Shefner’s research focuses on biomarker development and clinical therapeutics of amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy. He is co-founder and former co-chair of the Northeast ALS (NEALS) Clinical Trials Consortium, the largest ALS-dedicated group of its kind in the world. He continues to direct NEALS outcomes and clinical monitoring cores, currently involved in multiple clinical trials. His main research focus is the development of novel outcome measures for ALS trials.
Dr. Shefner has published more than 200 chapters and papers in peer- reviewed journals and has served on multiple grant review panels. He has also participated in committees organized by the Institute of Medicine to investigate the relationship between military service and ALS, as well as the health effects of Agent Orange on Vietnam War veterans. In 2014, Dr. Shefner received the Sheila Essey Award for ALS Research, the major award given annually by the ALS Association and the American Academy of Neurology. He is a Fellow of the American Academy of Neurology and the American Neurological Association, on the editorial boards of both the ALS Journal and Neurotherapeutics and is the neuromuscular section editor of UpToDate.